Monopar Therapeutics Inc. Share Price
MNPRMonopar Therapeutics Inc. Stock Performance
Open $53.29 | Prev. Close $54.42 | Circuit Range N/A |
Day Range $51.52 - $53.93 | Year Range $28.40 - $103.77 | Volume 6,186 |
Average Traded $53.05 |
Monopar Therapeutics Inc. Share Price Chart
About Monopar Therapeutics Inc.
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressing urokinase plasminogen activator receptor; and MNPR-101-Zr, a clinical-stage radiodiagnostic imaging agent comprised of MNPR-101 conjugated to zirconium-89. It develops MNPR-101-Lu, a late-preclinical stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225. The company has collaborations NorthStar to develop radio-immuno-therapeutics targeting severe COVID-19. The company was founded in 2014 and is headquartered in Wilmette, Illinois.
Monopar Therapeutics Inc. Historical Data
| Day | Open | Close | Change % |
|---|---|---|---|
29-Apr-26 | $53.29 | $51.75 | +0.00% |
29-Apr-26 | $53.29 | $51.75 | -5.39% |
28-Apr-26 | $54.44 | $54.70 | +2.22% |
27-Apr-26 | $53.62 | $53.51 | +1.74% |
24-Apr-26 | $53.01 | $52.59 | -0.58% |
23-Apr-26 | $52.90 | $52.90 | -0.82% |
22-Apr-26 | $52.62 | $53.34 | +1.72% |